Aparna Pharmaceuticals, a branch of the Aparna Group, recently announced its significant achievement in the pharmaceutical industry. Its manufacturing branch, Aparna Organics Limited, located in Pydibhimavaram, Srikakulam, Andhra Pradesh, India, has achieved the VAI classification. This acknowledgement was issued by the US Food and Drug Administration (USFDA) – making this a significant accomplishment for the company.
The announcement came as Aparna Pharmaceuticals is expanding into the pharmaceutical business. Aparna Organics Limited’s manufacturing facility had been inspected by USFDA in September 2023. Following the success of the audit, the pharmaceutical group has obtained the VAI certification.
Aparna Pharmaceuticals’ Managing Director, Rakesh Reddy, expressed their enthusiasm for this recognition, indicating, “Our facility’s compliance journey has been meticulous. We are thrilled to receive the USFDA’s stamp of approval. We are excited to contribute to global healthcare by delivering high-quality pharmaceutical APIs and intermediates.”
With the completion of the FDA audit, it has further established Aparna Pharmaceuticals as a leading manufacturer of APIs and Advanced Drug Intermediates. The group’s adherence to cGMP guidelines has led to producing high quality products, garnering worldwide recognition for the Aparna Pharmaceuticals.
